Avoid grapefruit
Avoid grapefruit and grapefruit juice.
Leaflet SYRLENO 10mg tablets
- Product code:
- W70719001
- Quantity:
- 10
- Indicated for:
- cancer; post-transplant immunosuppression
- Route of administration:
- oral
- Substance:
- everolimus (immunosuppressant)
- ATC
- L01EG02 — Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Mammalian target of rapamycin (MTOR) kinase inhibitors
Precautions:
Avoid live vaccines
Avoid live vaccines during treatment if contraindicated.
Immunosuppression / infection risk
This medicine may increase the risk of infections.
Major drug interactions
This medicine may have important interactions with other medicines.
Breastfeeding warning
Use during breastfeeding only on medical advice.
Pregnancy warning
Use during pregnancy only on medical advice.
Everolimus is a medication used in the treatment of certain types of cancer, as well as for preventing organ rejection after transplantation. It works by inhibiting a protein involved in cell growth and multiplication, thus helping to slow disease progression and reduce the risk of transplant rejection.
Everolimus is usually administered as tablets, according to the doctor's instructions, and the dose is adjusted depending on the condition being treated and the patient's response to therapy.
Side effects may include decreased immunity, infections, mouth ulcers, fatigue, digestive disorders, or increased blood sugar and cholesterol levels. In rare cases, severe reactions may occur, which is why careful monitoring is necessary during treatment.
Everolimus is an important option for patients with certain forms of cancer or who have undergone a transplant, helping to improve prognosis and increase the chances of treatment success.
Everolimus is usually administered as tablets, according to the doctor's instructions, and the dose is adjusted depending on the condition being treated and the patient's response to therapy.
Side effects may include decreased immunity, infections, mouth ulcers, fatigue, digestive disorders, or increased blood sugar and cholesterol levels. In rare cases, severe reactions may occur, which is why careful monitoring is necessary during treatment.
Everolimus is an important option for patients with certain forms of cancer or who have undergone a transplant, helping to improve prognosis and increase the chances of treatment success.
General data about SYRLENO 10mg
- Substance:
- everolimus
- Date of latest medicines list:
- 01-12-2024
- Product code:
- W70719001
- Concentration:
- 10mg
- Pharmaceutical form:
- tablets
- Quantity:
- 10
- Product type:
- Generic medicine
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for everolimus
Concentrations available for everolimus
- 0.1mg
- 0.25mg
- 0.5mg
- 0.75mg
- 10mg
- 1mg
- 2.5mg
- 2mg
- 3mg
- 5mg